Lipocine (NASDAQ:LPCN) has been given a $3.00 price objective by equities researchers at HC Wainwright in a report issued on Friday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 75.44% from the company’s current price.
A number of other analysts have also weighed in on the company. Ladenburg Thalmann Financial Services restated a “buy” rating and issued a $11.00 target price on shares of Lipocine in a research note on Thursday. Canaccord Genuity lowered Lipocine from a “buy” rating to a “hold” rating in a research note on Thursday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $13.50.
Shares of Lipocine (LPCN) opened at $1.71 on Friday. Lipocine has a 12 month low of $1.67 and a 12 month high of $5.33.
Large investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in Lipocine by 39.7% in the second quarter. Vanguard Group Inc. now owns 546,027 shares of the specialty pharmaceutical company’s stock worth $2,195,000 after purchasing an additional 155,110 shares during the period. P.A.W. Capital Corp acquired a new stake in Lipocine in the third quarter worth about $397,000. Goldman Sachs Group Inc. acquired a new stake in Lipocine in the second quarter worth about $300,000. Federated Investors Inc. PA increased its position in Lipocine by 9.2% in the second quarter. Federated Investors Inc. PA now owns 88,083 shares of the specialty pharmaceutical company’s stock worth $354,000 after purchasing an additional 7,429 shares during the period. Finally, Ameriprise Financial Inc. increased its position in Lipocine by 18.2% in the second quarter. Ameriprise Financial Inc. now owns 155,600 shares of the specialty pharmaceutical company’s stock worth $626,000 after purchasing an additional 24,000 shares during the period. Institutional investors own 22.06% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Lipocine (LPCN) Given a $3.00 Price Target by HC Wainwright Analysts” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/01/14/lipocine-lpcn-given-a-3-00-price-target-by-hc-wainwright-analysts.html.
Lipocine Company Profile
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.